COAGHemab Therapeutics Holdings, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Market cap
- $1.9B
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Takeover score 1 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo—Buybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo—Any vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo—Bottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$1.9B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$55M netNet sales over $10M in 12 months
Financials
No XBRL financials yet.
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| May 11, 2026 | AI DEN-MAB LLC | SCHEDULE 13D | 10.4% | Passive |
Insider trading
- Open-market buys, 12 mo
- $55M · 16
- Open-market sells, 12 mo
- $0 · 0
- Net
- $55M
Pay vs performance
No pay-versus-performance disclosure yet.